Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

Prospective Analysis of Patients with Metastatic Breast Cancer receiving Eribulin Mesylate as Second or More Lines of Chemotherapy: An Indian Experience

Background: Eribulin mesylate is a non-taxane microtubule inhibitor which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated patients...

Full description

Bibliographic Details
Main Authors:	BJ Srinivasa, Bhanu Prakash Lalkota, Girish Badarke, Diganta Hazarika, Nasiruddin Mohammad, Sulav Sapkota, Mansi Khanderia, D Tousif, Raghavendra Rao, Amritanshu Ram, Shekar Patil, Radheshyam Naik
Format:	Article
Language:	English
Published:	SAGE Publishing 2018-06-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	https://doi.org/10.1177/1179554918782475

Similar Items

Eribulin mesylate in the treatment of metastatic breast cancer
by: Jain S, et al.
Published: (2012-01-01)

Plasmablastic Lymphoma Involving Kidney in an HIV Positive Patient: A Case Report with Review of the Literature
by: Sulav Sapkota, et al.
Published: (2021-01-01)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
by: Yuan P, et al.
Published: (2021-02-01)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
by: Mu&ntilde;oz-Couselo E, et al.
Published: (2011-11-01)

Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.
by: Satoko Yamaguchi, et al.
Published: (2014-01-01)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
by: Carsten Nieder, et al.
Published: (2012-01-01)

Analysis of Peripherally Inserted Central Catheter Line in Cancer Patients: A Single-Center Experience
by: Sulav Sapkota, et al.
Published: (2020-10-01)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study.
by: Serena Di Cosimo, et al.
Published: (2019-01-01)

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy
by: Gabriel Tremblay, et al.

Eribulin mesylate use as third-line therapy in patients with metastatic breast cancer (VESPRY): a prospective, multicentre, observational study
by: Vincenzo Adamo, et al.
Published: (2019-12-01)

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
by: Lee Schwartzberg, et al.
Published: (2019-06-01)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
by: Sarah S. Mougalian, et al.
Published: (2018-09-01)

Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01)

Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01)

An Update on Advances in COVID-19 Laboratory Diagnosis and Testing Guidelines in India
by: K. S. Rajesh Kumar, et al.
Published: (2021-03-01)

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
by: Chris Twelves, et al.
Published: (2016-06-01)

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer
by: Chris Twelves, et al.
Published: (2016-01-01)

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial
by: Tetsu Hayashida, et al.
Published: (2018-06-01)

Quantitative determination of pefloxacin mesylate by residual-base neutralisation method
by: HULIKALCHANDRA SHEKAR PRAMEELA, et al.
Published: (2004-05-01)

Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial–mesenchymal transition and acts synergistically with 5-fluorouracil
by: Kurata T, et al.
Published: (2018-08-01)

Spare the warriors!
by: Mansi Khanderia
Published: (2020-01-01)

Isolated central nervous system blast crisis in a case of chronic myeloid leukemia on dasatinib
by: P K Kiran, et al.
Published: (2018-01-01)

COVID, stigma and karma
by: Mansi Haresh Khanderia
Published: (2021-01-01)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
by: Sharon Wilks, et al.
Published: (2015-01-01)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
by: Sharon Wilks, et al.
Published: (2015-10-01)

Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01)

Spectrophometric Determination of Nelfinavir Mesylate
by: K. Vanitha Prakash, et al.
Published: (2006-01-01)

A study of the mesylation of cellulose
by: Roberts, Richard
Published: (2005)

Eribulin and Confusion: A Previously Unknown Drug Side-Effect
by: Abu Baker Sheikh, et al.
Published: (2020-06-01)

Budget impact of eribulin in metastatic breast cancer in Russian Federation
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Stathmin dynamics modulate the activity of eribulin in breast cancer cells
by: Mikihiro Yoshie, et al.
Published: (2021-08-01)

Imatinib mesylate-induced palmoplantar keratoderma
by: Niharika Jha, et al.
Published: (2021-01-01)

Periorbital edema secondary to imatinib mesylate
by: Collin M McClelland, et al.
Published: (2010-05-01)

Eribulin Provides a Remarkable Effect in Trabectedin-Resistant Myxoid Liposarcoma
by: Hironari Tamiya, et al.
Published: (2020-01-01)

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
by: Victor C. Kok
Published: (2015-01-01)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
by: Wataru Goto, et al.
Published: (2020-12-01)

Eribulin in the Management of Advanced Breast Cancer: Implications of Current Research Findings
by: Victor C. Kok
Published: (2015-12-01)

Development of interstitial pneumonia during treatment with eribulin: a case report
by: Kota Nakamura, et al.
Published: (2017-11-01)

Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival
by: Thomas C, et al.
Published: (2016-09-01)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
by: Doherty MK, et al.
Published: (2015-01-01)